Senti Biosciences, Inc. (SNTI)

Over the past six months, Senti Biosciences' stock price has been impacted by several events. The company reported a net loss of $61.4 million for the full year 2025, leading to a stock decline. Senti Biosciences announced a publication in Cell Systems demonstrating advanced logic-gated CAR design for cell therapies and plans to implement a holding company reorganization. The company presented clinical and translational data on SENTI-202 at the 11th Annual Innate Killer Conference and participated in several healthcare conferences. SENTI-202 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Over the past 12 months, the stock has lost 69.7%.

As a clinical-stage biotechnology company, Senti Biosciences, Inc. is primarily focused on research and development of cell and gene therapies. There is no discernible demand seasonality for its products and services at this stage of its business operations. Demand for its future products, if approved, would likely be driven by disease prevalence and treatment efficacy rather than seasonal factors.

Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies. The company operates within the Pharmaceuticals & Biotech sector, specifically in the Biotechnology and Drug Discovery industries. Senti Biosciences leverages a proprietary synthetic biology platform to engineer Gene Circuits into new medicines, aiming to precisely target and eliminate cancer cells, spare healthy cells, increase specificity, and enable controllable drug expression even after administration. Its pipeline includes SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy for relapsed or refractory hematologic malignancies, SENTI-301A in development for hepatocellular carcinoma, and SENTI-401 aimed at detecting and eliminating colorectal cancer cells. The company also employs a Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform.

Senti Biosciences, Inc. is headquartered in South San Francisco, California, United States. The company's operations are primarily based in the U.S.

Senti Biosciences' reputation has been influenced by both positive scientific advancements and challenging financial performance. Positive developments include encouraging clinical data from the Phase 1 trial of SENTI-202 and the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202. The publication of research in Cell Systems also contributes to its scientific credibility. Challenges include significant financial difficulties, mounting losses, and a substantial decline in stock performance, which can negatively affect investor confidence and overall brand perception.

Senti Biosciences, Inc. has a mixed ownership structure, with institutional shareholders holding approximately 21.35% of the stock, insiders holding 97.33%, and retail investors holding 0.00%, according to one source. Other sources indicate varying percentages for institutional, insider, and retail ownership. Major institutional owners include NEA Management Company, LLC, Nantahala Capital Management, LLC, and Vanguard Group Inc. The largest individual shareholder is Celadon Partners Spv 24, owning 37.19% of the company.